Parabilis Pharmaceuticals IPO Raises $670 Million, Stock Surges 58%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: Fool
- Biotech Boom: In 2023, the biotech sector is thriving, with Parabilis Pharmaceuticals raising $670 million in its IPO, surpassing Moderna's previous record of $604 million, indicating strong investor interest in innovative cancer treatments.
- Stock Performance: Parabilis's stock surged 58% on its first trading day, closing above $31, reflecting positive market sentiment towards its unique drug development platform, potentially laying the groundwork for future commercialization.
- Rapid R&D Progress: The company's lead candidate, zolucatetide, is set to enter a phase 3 clinical trial for non-cancerous tumors in the first half of next year, with over 150 patients studied so far, showing promising initial data that could transform existing treatment options.
- Financial Challenges: Despite the successful IPO, Parabilis reported a loss of $145 million last year, with R&D expenses reaching $125 million, highlighting ongoing financial pressures that increase investment risks, particularly against the backdrop of high R&D costs in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 234.200
Low
190.00
Averages
218.50
High
240.00
Current: 234.200
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Alternatives Amid Tech Stock Surge
- Market Volatility Risk: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating a heavy reliance on tech, prompting investors to consider diversification to mitigate risks.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, demonstrates sustained innovation through its research-driven operations in pharmaceuticals and medical devices, ensuring it remains competitive in a fierce market.
- Stable Dividend Returns: With over 50 consecutive years of dividend increases, Johnson & Johnson has earned the title of 'Dividend King', reflecting its strong execution and business resilience, appealing to investors seeking stable returns.
- Healthcare Sector Resilience: Demand for medical services remains steady during economic downturns, and Johnson & Johnson's business exhibits higher stability amid economic fluctuations, making it a solid alternative to tech stocks.
See More
Tech Stock Weighting High, J&J as a Stable Alternative
- Tech Stock Weight Analysis: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating Wall Street's heavy reliance on tech and suggesting that investors may need to diversify to mitigate risk.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, maintains competitiveness through its R&D-driven operations in pharmaceuticals and medical devices, demonstrating a long-term commitment to innovation.
- Dividend King Status: With over 50 consecutive years of dividend increases, Johnson & Johnson showcases its strong and consistent execution, making it a reliable choice for investors, especially during economic fluctuations.
- Resilience of Healthcare Sector: Compared to tech stocks, the healthcare sector exhibits greater stability, as individuals prioritize spending on life-saving medical care even during economic downturns, positioning Johnson & Johnson as an ideal alternative when tech stocks face pressure.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
Johnson & Johnson CEO Reaffirms No Plans for GLP-1 Market
- Clear Market Positioning: CEO Joaquin Duato stated that Johnson & Johnson will not enter the rapidly growing GLP-1 obesity drug market, instead focusing on treatments for diseases like cancer, reflecting a strategic decision in oncology.
- Growth Target Set: Duato emphasized that J&J aims to become the world's leading cancer drug maker by 2030, indicating the company's commitment to cancer treatment as a key growth pillar.
- Ongoing R&D Investment: Despite previous failures in Alzheimer's research, J&J continues to invest in R&D for neurodegenerative diseases, showcasing its concern and responsibility towards significant public health issues.
- Business Restructuring Progress: Following the spin-off of its consumer healthcare business in 2023, J&J is in the early phase of its growth cycle, with plans to separate its orthopedics unit, indicating potential in its pharma and MedTech divisions.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Investment Alternatives Amid Tech Stock Surge
- Market Volatility Risk: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating a heavy reliance on tech, prompting investors to consider diversification to mitigate risks.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, demonstrates sustained innovation through its research-driven operations in pharmaceuticals and medical devices, ensuring it remains competitive in a fierce market.
- Stable Dividend Returns: With over 50 consecutive years of dividend increases, Johnson & Johnson has earned the title of 'Dividend King', reflecting its strong execution and business resilience, appealing to investors seeking stable returns.
- Healthcare Sector Resilience: Demand for medical services remains steady during economic downturns, and Johnson & Johnson's business exhibits higher stability amid economic fluctuations, making it a solid alternative to tech stocks.
See More
Tech Stock Weighting High, J&J as a Stable Alternative
- Tech Stock Weight Analysis: Technology stocks account for nearly 40% of the S&P 500 index, with a weighting more than three times that of the next largest sector, indicating Wall Street's heavy reliance on tech and suggesting that investors may need to diversify to mitigate risk.
- Strong Innovation Capability: Johnson & Johnson, as one of the world's largest healthcare companies, maintains competitiveness through its R&D-driven operations in pharmaceuticals and medical devices, demonstrating a long-term commitment to innovation.
- Dividend King Status: With over 50 consecutive years of dividend increases, Johnson & Johnson showcases its strong and consistent execution, making it a reliable choice for investors, especially during economic fluctuations.
- Resilience of Healthcare Sector: Compared to tech stocks, the healthcare sector exhibits greater stability, as individuals prioritize spending on life-saving medical care even during economic downturns, positioning Johnson & Johnson as an ideal alternative when tech stocks face pressure.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
Johnson & Johnson CEO Reaffirms No Plans for GLP-1 Market
- Clear Market Positioning: CEO Joaquin Duato stated that Johnson & Johnson will not enter the rapidly growing GLP-1 obesity drug market, instead focusing on treatments for diseases like cancer, reflecting a strategic decision in oncology.
- Growth Target Set: Duato emphasized that J&J aims to become the world's leading cancer drug maker by 2030, indicating the company's commitment to cancer treatment as a key growth pillar.
- Ongoing R&D Investment: Despite previous failures in Alzheimer's research, J&J continues to invest in R&D for neurodegenerative diseases, showcasing its concern and responsibility towards significant public health issues.
- Business Restructuring Progress: Following the spin-off of its consumer healthcare business in 2023, J&J is in the early phase of its growth cycle, with plans to separate its orthopedics unit, indicating potential in its pharma and MedTech divisions.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
